Quarterly report pursuant to Section 13 or 15(d)

Condensed Interim Consolidated Balance Sheets

v3.19.3
Condensed Interim Consolidated Balance Sheets - USD ($)
Aug. 31, 2019
Nov. 30, 2018
CURRENT ASSETS    
Cash and cash equivalents $ 1,881,377 $ 1,182,387
Accounts receivable 112,140 18,914
Inventory 666,912 129,121
Deferred cost 55,862  
Prepaid expenses and other receivables 793,420 901,247
Total Current Assets 3,509,711 2,231,669
Patent rights 100,835 106,334
Deposit for equipment 227,781 205,664
Property and equipment 274,109 113,418
TOTAL ASSETS 4,112,436 2,657,085
CURRENT LIABILITIES    
Accounts payable and accrued liabilities 862,400 397,309
Deferred revenue 13,320  
Secured convertible debentures   978,361
Convertible notes 1,924,957  
Derivative liabilities 214,200 957,301
Total Current Liabilities 3,014,877 2,332,971
Long term convertible notes 1,277,676 167,077
Total Liabilities 4,292,553 2,500,048
Capital stock    
Preferred stock, $0.001 par value, 5,000,000 shares authorized, Nil issued and outstanding (November 30, 2018 - nil).
Common stock, $0.001 par value 300,000,000 shares authorized, 104,021,837 issued and outstanding (November 30, 2018: 101,976,900) 104,022 101,977
Additional paid-in capital 35,752,050 33,341,695
Shares to be issued 20,000  
Accumulated deficit (35,941,684) (33,252,338)
Accumulated other comprehensive loss (114,505) (34,297)
Total Stockholders' (Deficiency) Equity (180,117) 157,037
TOTAL LIABILITIES AND STOCKHOLDERS' (DEFICIENCY) EQUITY $ 4,112,436 $ 2,657,085